Yes. It does. Continuously. And in healthcare, the cost of wrong is higher than in any other category.
AI engines hallucinate. They confuse similar entities. They merge timelines. They invent citations. They blend a recall on one device into the safety record of another. They attribute one physician's malpractice case to a different physician with the same name. They name a drug as approved when it is in trials. They name a hospital as accredited when its accreditation was suspended. They confuse a company's two product lines and report adverse events from one against the other.
In other categories, the consequences are inconvenient. In healthcare, the consequences are clinical, regulatory, and litigated. This is the most expensive failure mode in AI communications for healthcare.
I've formatted it with H3 headings only, preserving the exact wording, style, and flow.
The clinical risk.
A patient who acts on a wrong AI answer can take a wrong medication, choose a wrong provider, decline a needed treatment, or pursue a contraindicated therapy. The brand named in the wrong answer is exposed to outcomes it did not produce — and to liability the legacy comms playbook is not structured to manage.
The regulatory risk.
The FDA, the FTC, and state attorneys general are watching how AI engines describe regulated products. A model that overstates an indication, understates a side effect, or implies a comparative claim the brand did not make creates regulatory exposure for the brand — even when the brand did not author the offending content. Pharmaceutical comms teams now have to monitor what models say about their products and document the corrective steps they take when the model is wrong. The documentation requirement is real, and legal teams that have not absorbed it will absorb it the hard way.
The litigation risk.
A plaintiff attorney can run a structured AI query against a brand and surface wrong, damaging, or misleading framing the model produced from sources the brand did not control. That framing becomes discoverable. The brand's failure to monitor and correct becomes part of the negligence argument. We did not know what the model said about us is not a defense.
The commercial risk.
A wrong AI answer can crater pipeline before the brand sees the input data shift. Prescribers, payers, procurement teams, and patients are all running queries the brand cannot observe. By the time the commercial impact shows up in a refill rate, a formulary decision, a contract renewal, or a patient volume report, the wrong answer has been compounding for months.
The defense is not to demand the models be perfect.
It is to build the operational discipline of continuous correction.
One. Monitoring.
Structured, scheduled, recurring queries against every major engine across every category prompt that matters. Not a one-time audit. A continuous capability.
Two. Source-layer correction.
When the model surfaces a wrong fact, the correction has to be seeded into the sources the model reads — not just published on the brand's own site. The brand's own site is rarely weighted heavily enough to shift the model's answer on its own.
Three. Stacked authority.
A single corrective citation can be displaced by a hundred uncorrected ones. The correction has to be stacked across multiple high-weight sources to shift the model's framing.
Four. Documentation.
Every monitored error and every corrective step has to be documented. The documentation is regulatory hygiene, litigation defense, and operational discipline at the same time.
Five. Internal alignment.
Comms, medical affairs, regulatory, legal, and digital all have to operate from the same monitoring dashboard. Brands running this in silos are slower than brands running it as a single function — and slow, in this discipline, is expensive.
AI engines will keep getting things wrong about healthcare brands. They will get fewer things wrong over time. They will never get nothing wrong. The brands that build for continuous correction absorb the errors without commercial damage. The brands that don't absorb them the slow way — through a clinical event, a regulatory action, a litigation development, or a quarterly miss they cannot trace back to the wrong answer that started it.
The error is not the brand's fault. The failure to defend against it will be.
